| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. | Director | Common Stock | 99,486 | $298,458 | $3.00 | 11 Jun 2025 | Direct |
| Aquestive Therapeutics, Inc. | Director | Stock Option (Right to Purchase) | 42,000 | $143,220 | $3.41 | 11 Jun 2025 | Direct |
| Crestline Lending Solutions, LLC | Chief Operating Officer | Limited Liability Company Units | 0 | 29 Oct 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| N/A | Crestline Lending Solutions, LLC | 29 Oct 2025 | 0 | $0 | 3 | Chief Operating Officer | 29 Oct 2025, 17:44 |
| AQST | Aquestive Therapeutics, Inc. | 11 Jun 2025 | 1 | +$143,220 | 4 | Director | 12 Jun 2025, 13:58 |
| AQST | Aquestive Therapeutics, Inc. | 20 Jun 2024 | 1 | $0 | 4 | Director | 21 Jun 2024, 13:50 |
| AQST | Aquestive Therapeutics, Inc. | 21 Jun 2023 | 1 | $0 | 4 | Director | 23 Jun 2023, 12:24 |
| AQST | Aquestive Therapeutics, Inc. | 22 Jun 2022 | 1 | $0 | 4 | Director | 24 Jun 2022, 17:13 |
| AQST | Aquestive Therapeutics, Inc. | 15 Jun 2021 | 1 | $0 | 4 | Director | 17 Jun 2021, 18:51 |
| AQST | Aquestive Therapeutics, Inc. | 10 May 2021 | 1 | $0 | 4 | Director | 01 Jun 2021, 16:11 |